WALTHAM, Mass, May 29, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T ...
TScan Therapeutics Inc. (NASDAQ:TCRX), a clinical-stage biopharmaceutical company with a market capitalization of $139.57 million, is poised at a critical juncture in its development of innovative ...
Location: Stars at Night B2 & B3 (Ballroom Level, Henry B. González Convention Center) A copy of the presentation materials will be added to the “Events and Presentations” section of the Company’s ...
Ratings for TScan Therapeutics (NASDAQ:TCRX) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below offers a condensed view of ...
Amgen Inc AMGN and TScan Therapeutics Inc TCRX announced a multi-year collaboration to use TScan's proprietary target discovery platform, TargetScan, to identify the antigens recognized by T cells in ...
Analysts' ratings for TScan Therapeutics (NASDAQ:TCRX) over the last quarter vary from bullish to bearish, as provided by 7 analysts. The following table summarizes their recent ratings, shedding ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results